| Background and Objective:Ovarian cancer (epithelial ovarian cancer) is the leading cause of gynecological cancer death worldwide. Despite advances in surgical and chemotherapy management, ovarian cancer mortality has remained virtually unchanged. This may due to two maincauses: One reason is the relatively asymptomatic nature of early stage disease,combined with the anatomical location of the ovaries deep in the pelvic. As a result, more than 70% of ovarian cancer is usually diagnosed at an advanced stage. Another reason is that the diseases usually relapse or progress after a short disease-free period. Therefore, it is important to search new early diagnostic method and to discovery new biomarkers for monitoring treatment response which can early warning the relapse and/or metastasis. Thus, clinician can successfully improve the total survival rate for ovarian cancer.Nowadays there are much difficulty in early detection and treatment monitoring for ovarian cancer. Clinical examination, ultrasonograph and serum biomarker detection are the main methods for ovarian cancer detection. Cancer antigen 125 (CA125) is the most widely used biomarker for ovarian cancer. Although concentration of CA125 are abnormal in about 80% of patients with advanced-stage, they are increased in only 50~60% of patients with stage I ovarian cancer. CA125 has a positive predictive value of less than 10% as a single marker, and the addition of...
|
PDF Full Text Request